Clinical trial
Study of Amantadine for Weight Stabilization During Olanzapine Treatment
NCT00287352 · University of North Carolina, Chapel Hill, Other · Completed
Key facts
| NCT number | NCT00287352 |
|---|---|
| Title | Study of Amantadine for Weight Stabilization During Olanzapine Treatment |
| Official title | Double Blind Placebo Controlled Investigation of Amantadine for Retarding Weight Gain in First Episode Adlt Psychotic Subjects Beginning Therapy With Olanzapine. |
| Lead sponsor | University of North Carolina, Chapel Hill, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features |
| Intervention type | Drug |
| Interventions | Olanzapine, Amantadine, Olanzapine and placebo |
| Enrollment | 40 |
| Start date | May 1, 2005 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Feb 6, 2006 |
| Last update posted | May 2, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: